Logo image of PTHS

PELTHOS THERAPEUTICS INC (PTHS) Stock Fundamental Analysis

USA - NYSEARCA:PTHS - US1711262048 - Common Stock

34.4 USD
-3.02 (-8.07%)
Last: 11/7/2025, 8:10:04 PM
34.5 USD
+0.1 (+0.29%)
After Hours: 11/7/2025, 8:10:04 PM
Fundamental Rating

0

Taking everything into account, PTHS scores 0 out of 10 in our fundamental rating. PTHS was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of PTHS have multiple concerns. PTHS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PTHS has reported negative net income.
In the past 5 years PTHS always reported negative net income.
PTHS had a negative operating cash flow in each of the past 5 years.
PTHS Yearly Net Income VS EBIT VS OCF VS FCFPTHS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

The Return On Assets of PTHS (-1098.30%) is worse than 97.95% of its industry peers.
Industry RankSector Rank
ROA -1098.3%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTHS Yearly ROA, ROE, ROICPTHS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PTHS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTHS Yearly Profit, Operating, Gross MarginsPTHS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, PTHS has more shares outstanding
The debt/assets ratio for PTHS has been reduced compared to a year ago.
PTHS Yearly Shares OutstandingPTHS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PTHS Yearly Total Debt VS Total AssetsPTHS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

2.2 Solvency

PTHS has an Altman-Z score of -82.40. This is a bad value and indicates that PTHS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -82.40, PTHS is doing worse than 95.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -82.4
ROIC/WACCN/A
WACCN/A
PTHS Yearly LT Debt VS Equity VS FCFPTHS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

2.3 Liquidity

A Current Ratio of 0.11 indicates that PTHS may have some problems paying its short term obligations.
PTHS's Current ratio of 0.11 is on the low side compared to the rest of the industry. PTHS is outperformed by 96.46% of its industry peers.
A Quick Ratio of 0.11 indicates that PTHS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.11, PTHS is doing worse than 96.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
PTHS Yearly Current Assets VS Current LiabilitesPTHS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

PTHS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2876.09%.
EPS 1Y (TTM)-2876.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.64% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.62%
EPS Next 2Y34.04%
EPS Next 3Y23.34%
EPS Next 5Y16.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTHS Yearly Revenue VS EstimatesPTHS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
PTHS Yearly EPS VS EstimatesPTHS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTHS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTHS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTHS Price Earnings VS Forward Price EarningsPTHS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTHS Per share dataPTHS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8 -10

4.3 Compensation for Growth

PTHS's earnings are expected to grow with 23.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.04%
EPS Next 3Y23.34%

More info and screens

0

5. Dividend

5.1 Amount

PTHS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PELTHOS THERAPEUTICS INC

NYSEARCA:PTHS (11/7/2025, 8:10:04 PM)

After market: 34.5 +0.1 (+0.29%)

34.4

-3.02 (-8.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)N/A N/A
Inst Owners10.36%
Inst Owner ChangeN/A
Ins Owners2.61%
Ins Owner Change96.31%
Market Cap105.61M
Revenue(TTM)N/A
Net Income(TTM)-9.04M
Analysts85
Price Target56.1 (63.08%)
Short Float %2.22%
Short Ratio1.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)-27.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-900%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)133.02%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.08
EYN/A
EPS(NY)-2.6
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-2.12
TBVpS-2.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1098.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -82.4
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2876.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.55%
EPS Next Y-3.62%
EPS Next 2Y34.04%
EPS Next 3Y23.34%
EPS Next 5Y16.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-196.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.4%
OCF growth 3YN/A
OCF growth 5YN/A

PELTHOS THERAPEUTICS INC / PTHS FAQ

What is the ChartMill fundamental rating of PELTHOS THERAPEUTICS INC (PTHS) stock?

ChartMill assigns a fundamental rating of 0 / 10 to PTHS.


Can you provide the valuation status for PELTHOS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to PELTHOS THERAPEUTICS INC (PTHS). This can be considered as Overvalued.


How profitable is PELTHOS THERAPEUTICS INC (PTHS) stock?

PELTHOS THERAPEUTICS INC (PTHS) has a profitability rating of 0 / 10.


What is the financial health of PELTHOS THERAPEUTICS INC (PTHS) stock?

The financial health rating of PELTHOS THERAPEUTICS INC (PTHS) is 0 / 10.